Evotec SE and Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (“ASO”) therapies to address challenging or previously undruggable targets via its LNAplus™ platform, have expanded their strategic partnership in the field of ASO-based therapeutics.
Read More
